Nephrology · 3 h ago
Pentoxifylline Lowers Albuminuria in Diabetic Kidney Disease, but Hard Outcomes Remain Uncertain
This meta-analysis included 34 randomized trials of oral pentoxifylline in people with diabetic kidney disease. Albuminuria was lower with treatment, but results were highly heterogeneous, and evidence for kidney failure or death was sparse.
- Albuminuria was lower, but trial results varied substantially.
- GFR estimates were imprecise in lower-risk trials.
- Kidney failure and death were rarely assessed.
- Gastrointestinal adverse events were more frequent.
Researchers reviewed randomized trials of oral pentoxifylline for diabetic kidney disease published through June 2026. Thirty-four studies were included, with 32 contributing data. The co-primary surrogate outcomes were albuminuria and change in glomerular filtration rate (GFR); the primary hard outcome was end-stage kidney disease or death. Random-effects models were used, with risk of bias and evidence sufficiency assessed.
Across 22 studies, albuminuria was lower with pentoxifylline (ratio of means 0.69, 95% CI 0.50–0.94). However, heterogeneity was extreme (I²=97%), the prediction interval included substantial benefit and harm (0.15–3.10), and only 53% of the required information had accrued. In five studies with at least 12 months of follow-up, GFR change favored treatment by 4.49 mL/min/1.73 m² (95% CI 0.84–8.14), but estimates from two lower-risk or some-concerns trials were imprecise. Only 29 kidney failure or death events were reported across six studies; the risk ratio was 0.90 (95% CI 0.46–1.77).
Gastrointestinal adverse events were more common with pentoxifylline (risk ratio 3.00, 95% CI 1.94–4.64), while serious adverse events were not clearly increased. The authors conclude that the surrogate evidence is uncertain and hard outcomes have scarcely been tested; they call for an adequately powered, long-term trial. These findings do not establish that pentoxifylline prevents kidney failure or death.
In practice
For people with diabetic kidney disease, this review found lower albuminuria with oral pentoxifylline, but the effect varied markedly between trials and may not be reproduced. Evidence for preservation of GFR is limited and imprecise, while kidney failure or death was assessed in only a small number of studies with few events. Gastrointestinal adverse events were more common. The findings do not establish a hard-outcome benefit; the authors identify a long-term, adequately powered trial as the priority.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nephrology Dialysis Transplantation: Pentoxifylline for chronic kidney disease in people with diabetes: a meta-analysis of randomized trials ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.